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The eukaryotic nicotinamide riboside kinase (Nrk) pathway, which is induced in response to nerve damage and
promotes replicative life span in yeast, converts nicotinamide riboside to nicotinamide adenine dinucleotide (NAD
þ)b y
phosphorylation and adenylylation. Crystal structures of human Nrk1 bound to nucleoside and nucleotide substrates
and products revealed an enzyme structurally similar to Rossmann fold metabolite kinases and allowed the
identification of active site residues, which were shown to be essential for human Nrk1 and Nrk2 activity in vivo.
Although the structures account for the 500-fold discrimination between nicotinamide riboside and pyrimidine
nucleosides, no enzyme feature was identified to recognize the distinctive carboxamide group of nicotinamide
riboside. Indeed, nicotinic acid riboside is a specific substrate of human Nrk enzymes and is utilized in yeast in a novel
biosynthetic pathway that depends on Nrk and NAD
þsynthetase. Additionally, nicotinic acid riboside is utilized in vivo
by Urh1, Pnp1, and Preiss-Handler salvage. Thus, crystal structures of Nrk1 led to the identification of new pathways to
NAD
þ.
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þ. PLoS Biol 5(10): e263.
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Introduction
NAD
þ functions both as a co-enzyme for hydride transfer
reactions and as a substrate for NAD
þ-consuming enzymes
including Sirtuins and poly(ADPribose) polymerases [1]. Most
fungal and animal cells have redundant pathways for NAD
þ
biosynthesis that consist of a de novo pathway from
tryptophan [2] and salvage pathways that utilize the vitamin
precursors of NAD
þ, namely nicotinic acid (Na), nicotinamide
(Nam) [3], and nicotinamide riboside (NR) [4]. Because NAD
þ
biosynthesis is required for the function of Sirtuins [5–9] and
given the evidence that Sirtuins play roles in life span
extension [10–12], increased mitochondrial function [13], and
energy expenditure [14], there has been a resurgence of
interest in NAD
þ-boosting drug therapies and nutritional
interventions [1].
NR, a natural product present in milk [4], increases NAD
þ
biosynthesis, increases Sir2-dependent gene silencing, and
extends yeast life span via two NR salvage pathways [15]. The
ﬁrst NR salvage pathway depends on NR phosphorylation by
a speciﬁc kinase, encoded by the products of the yeast and
human NRK1 genes or the human NRK2 gene [4]. The second
NR salvage pathway is Nrk-independent and is initiated by
the activity of yeast Urh1, Pnp1 , and, to a slight degree, Meu1,
which split NR into a ribosyl product and Nam for resynthesis
of NAD
þ via Nam salvage [15]. Although the second pathway
of NR salvage has yet to be investigated in mammalian
systems, Pnp1 and Meu1 are the yeast homologs of human
purine nucleoside phosphorylase and methylthioadenosine
phosphorylase, suggesting that human NR salvage may
depend on Nrk1, Nrk2, and Pnp [15].
Na, Nam, and NR have been investigated in an ex vivo
model of murine dorsal root ganglion neurodegeneration
[16]. Prompted by genetic evidence that increased neuronal
NAD
þ biosynthesis protects against Wallerian degeneration
[17,18], NR was shown to be the only NAD
þprecursor vitamin
that protects against axonopathy without engineered over-
expression of a biosynthetic gene, apparently because the
NRK2 gene is transcriptionally induced by nerve damage [16].
NR kinases are ;200–amino acid polypeptides related to
human uridine/cytidine kinase 2 [19] and Escherichia coli
pantothenate kinase [20]. To establish that yeast Nrk1 and
no other enzyme phosphorylates NR in vivo, Saccharomyces
cerevisiae mutants without the QNS1 gene, encoding gluta-
mine-dependent NAD
þ synthetase [21] were shown to be
entirely dependent on NR and Nrk1 for viability [4]. The
human homologs Nrk1 and Nrk2 were validated in the same
assay [4]. The presence of a human Nrk pathway suggests the
means by which the anticancer prodrug tiazofurin [22] may
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PLoS BIOLOGYbe converted to the toxic NAD
þantagonist tiazofurin adenine
dinucleotide (TAD).
Although yeast and human Nrk1 and human Nrk2 were
puriﬁed and characterized with respect to NR, cytidine,
uridine, and tiazofurin phosphorylation in speciﬁc activity
terms [4], the kinetics of nucleoside and nucleoside triphos-
phate speciﬁcity have not been carefully quantiﬁed. Here we
report the structure–activity relationships for human NR
kinases with nucleoside and nucleoside triphosphate sub-
strates. Nrk1 and Nrk2 both strongly discriminate against
cytidine phosphorylation by 500-fold in kcat/KM. However,
Nrk1 effectively phosphorylates NR with ATP or GTP and
discriminates against uridine, whereas Nrk2 discriminates
against GTP as a phosphodonor but does not strongly
discriminate against phosphorylation of uridine. To dissect
the structural basis for speciﬁcity, we crystallized selenome-
thionyl human Nrk1 bound to Mg
2þ ADP and solved the 1.95
A ˚ structure of the Nrk1 monomer by single-wavelength
anomalous scattering. Using a series of crystal structures of
human Nrk1 bound to NR, NR Mg
2þ adenosine-59-[(b,c)-
imido]triphosphate (AppNHp), and nicotinamide mononu-
cleotide (NMN), we resolved snapshots of the catalytic cycle
and identiﬁed two conserved carboxylate groups that we
establish as essential for biological activity. From a structure
of Nrk1 bound to tiazofurin, we gained further under-
standing of nucleoside speciﬁcity. However, at the site where
we expected to ﬁnd speciﬁc enzyme features that would
recognize the distinctive carboxamide portion of NR and
tiazofurin substrates, we found only steric complementarity
and solvent exposure. Accordingly, we synthesized nicotinic
acid riboside (NaR) and found this molecule to be as speciﬁc a
biochemical substrate as is NR. Finally, we showed that NaR is
a synthetic vitamin precursor of NAD
þ that supports the
growth of yeast cells through each of the salvage pathways—
Nrk and Urh1/Pnp1—also used by NR. Thus, NR kinases are
actually dual-speciﬁcity salvage enzymes that may play a role
in another unanticipated biosynthetic pathway to NAD
þ.
Results
Substrate Specificity of Recombinant Nrk1 and Nrk2
To assess Nrk speciﬁcity in vitro, recombinant human Nrk1
and Nrk2 were expressed in E. coli and puriﬁed by immobilized
metal chelate afﬁnity chromatography. As shown in Table 1,
the enzymes discriminate between substrates almost entirely
in the KM term. Nrk1 has a kcat of approximately 0.5 s
 1
irrespective of substrate, and Nrk2 possesses a kcat of
approximately 1 s
 1 irrespective of substrate. Nrk1 strongly
favors NR as a substrate, displaying a 340-fold preference for
NR over cytidine in the KM term and a ;500-fold preference
over either cytidine or uridine in the kcat/KM term. Tiazofurin,
the prodrug form of the toxic NAD
þ analog TAD, is a
relatively good Nrk1 substrate with a kcat/KM of 1300 s
 1M
 1,
which represents 19% of the second-order rate for NR
conversion to NMN (6800 s
 1M
 1). Moreover, Nrk1 shows
little preference for ATP (6800 s
 1M
 1) over GTP (5000
s
 1M
 1) as phosphodonor in formation of NMN.
Whereas these data would classify Nrk1 as an NR and
tiazofurin:ATP or GTP kinase, the data establish Nrk2 as an
ATP-speciﬁc NR, tiazofurin, and uridine kinase. As shown in
Table 1, with GTP as the phosphodonor, Nrk2 has only 1.5%
of the NR phosphorylating activity with respect to ATP.
Tiazofurin (4500 s
 1M
 1) is phosphorylated as well as NR
(3900 s
 1M
 1), and uridine (850 s
 1M
 1) is within 5-fold of NR.
The fact that Nrk1 and Nrk2 are distinct from uridine/
cytidine kinases [19] is underscored by the poor cytidine
monophosphate-forming activity of each enzyme.
Table 1. Substrate Specificity of Human Nicotinamide Riboside Kinases
Substrates Nrk1 Nrk2
KM (mM) kcat (s
 1) kcat/KM (s
 1M
 1) KM (mM) kcat (s
 1) kcat/KM (s
 1M
 1)
NR þ ATP 0.088 6 0.008 0.60 6 0.04 6,800 0.19 6 0.03 0.75 6 0.05 3,900
NR þ GTP 0.068 6 0.005 0.34 6 0.01 5,000 30 6 7 1.7 6 0.4 57
TZ þ ATP 0.27 6 0.05 0.35 6 0.09 1,300 0.11 6 0.03 0.49 6 0.07 4,500
Urd þ ATP 17. 6 2. 0.21 6 0.03 12 1.3 6 0.2 1.1 6 0.2 850
Cyd þ ATP 30. 6 8. 0.48 6 0.14 16 15. 6 2. 0.82 6 0.10 55
NaR þ ATP 0.051 6 0.015 0.21 6 0.01 4,100 0.063 6 0.02 0.34 6 0.05 5,400
TZ, tiazofurin; Urd, uridine; Cyd, cytidine.
doi:10.1371/journal.pbio.0050263.t001
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Author Summary
Biosynthesis of nicotinamide adenine dinucleotide (NAD
þ)i s
fundamental to cells, because NAD
þ is an essential co-factor for
metabolic and gene regulatory pathways that control life and death.
Two vitamin precursors of NAD
þ were discovered in 1938. We
recently discovered nicotinamide riboside (NR) as a third vitamin
precursor of NAD
þ in eukaryotes, which extends yeast life span
without caloric restriction and protects damaged dorsal root
ganglion neurons from degeneration. Biosynthesis of NAD
þ from
NR requires enzyme activities in either of two pathways. In one
pathway, specific NR kinases, including human Nrk1 and Nrk2,
phosphorylate NR to nicotinamide mononucleotide. A second and
Nrk-independent pathway is initiated by yeast nucleoside-splitting
enzymes, Urh1 and Pnp1. We solved five crystal structures of human
Nrk1 and, on the basis of co-crystal structures with substrates,
suggested that the enzyme might be able to phosphorylate a novel
compound, nicotinic acid riboside (NaR). We then demonstrated
that human Nrk enzymes have dual specificity as NR/NaR kinases in
vitro, and we established the ability of NaR to be used as a vitamin
precursor of NAD
þvia pathways initiated by Nrk1, Urh1, and Pnp1 in
living yeast cells. Thus, starting from the structure of human Nrk1,
we discovered a synthetic vitamin precursor of NAD
þ and suggest
the possibility that NaR is a normal NAD
þ metabolite.Structural Basis of Substrate Specificity
To understand the basis for substrate speciﬁcity of human
Nrk1, we prepared a selenomethionyl form of human Nrk1
and grew single crystals of a complex of the enzyme with
Mg
2þ ADP. A crystal, which had the symmetry of C2221, was
subjected to 0.9793-A ˚ synchrotron X-radiation, and produced
nearly complete diffraction data to 1.9-A ˚ resolution (Table 2).
Single-wavelength anomalous scattering [23] allowed location
of Se sites [24] and phasing [25] to produce an interpretable
experimental electron density map of the Nrk1 monomer
prior to model building. The 1.95-A ˚ reﬁned protein model
includes residues 1–82 and 92–189 of the 199–amino acid
polypeptide, plus ADP, Mg
2þ, and 72 water molecules with B
factors between 9 and 37 A ˚ 2.
As shown in Figure 1A, Nrk1 consists of a ﬁve-stranded b
sheet ﬂanked on one side by a helices, E and A, and on the
other side by helix B. Additionally, the monomeric enzyme
contains a lid domain consisting of helix C and D connected
by a 12– amino acid loop. The ﬁve-stranded sheet is entirely
parallel and is formed from strands 2, 3, 1, 4, and 5 in the
primary sequence. Earlier [4], we detected sequence similarity
with uridine/cytidine kinase and pantothenate kinase. Indeed,
the DALI structural similarity server [26] revealed Nrk1 to be
a structural homolog of a variety of Rossmann fold-contain-
ing metabolite kinases including human uridine/cytidine
kinase 2 Uck2 [27], E. coli pantothenate kinase panK [20],
Bacillus stearothermophilus adenylate kinase [28] and E. coli
gluconate kinase [29]. A structural superposition of Nrk1 and
Uck2 is provided in Figure 1B.
The ADP-binding site, including P-loop [30] sequence Gly-
Val-Thr-Asn-Ser-Gly-Lys-Thr (residues 10–17), is shown in
close-up in Figure 2A. The guanidino group of Arg132, the e
amino group of Lys16, and the hydroxyl of Thr18 coordinate
the b and a phosphates of ADP, whereas the hydroxyl of
Thr17, a b phosphate oxygen, and four well-ordered water
molecules coordinate the magnesium ion. The adenine ring
of ADP lies between Arg128 and Glu174. Accounting for the
ATP/GTP nonspeciﬁcity of Nrk1, the 2 carbon of adenine is
solvent exposed such that the 2 amino group of guanine
would not appear to preclude binding in the same manner.
Table 2. Crystallization, Data Collection, and Refinement
Data Parameter Crystal Structure
ADP NMN Tiazofurin NR
a AppNHp þ NR
Crystallization Ligands added 10 mM ADP, 20 mM MgCl2 10 mM NMN,
20 mM MgCl2
10 mM tiazofurin, 1,mM
ADP, 20,mM MgCl2
10 mM NR,10 mM
AppNHp, 20 mM MgCl2
10 mM NR,
10 mM AppNHp,
20 mM MgCl2
PDB code 2QSY 2QSZ 2P0E 2QT1 2QT0
Crystallization 20% PEG 3350, 0.2 M NaH2PO4,
150mM D-Sucrose, 0.1M HEPES,
pH 7.0
22% PEG 4000,
0.2 M NH4SO4,
Na Acetate, pH 5.2
25% PEG 3350,
0.2 M NaH2PO4,
0.1 M Bicine, pH 9.0
15% PEG 3350,
0.2 M NaH2PO4,
0.1 M Bis-Tris, pH 6.0
35% PEG 2000
mono-methylether,
0.1 M Tris, pH 8.0
Data collection X-ray source APS 17ID Rigaku FR-E Rigaku FR-E APS 23ID-D Rigaku FR-E
Wavelength (A ˚) 0.97931 1.5418 1.5418 0.97934 1.5418
Space group C2221 C2221 C2221 C2221 P41212
Cell dimensions
a, b, c (A ˚)
54.45, 142.07, 62.26 55.92, 142.34, 62.43 55.61, 141.57, 62.00 55.53, 141.91, 62.06 97.02, 97.02, 44.80
Resolution (A ˚) 50.00–1.90 (1.97–1.90) 30.00–1.90 (1.97–1.90) 20.00–1.80 (1.86–1.80) 40.00–1.32 (1.37–1.32) 30.00–1.92 (1.99–1.92)
Rsym 0.122 (0.709) 0.138 (0.901) 0.089 (0.526)
b 0.129 (0.599) 0.086 (0.999)
I / rI 17.7 (2.4) 15.8 (1.8) 30.7 (4.9)
b 17.9 (1.2) 29.2 (2.3)
Completeness (%) 99.6 (96.6) 99.1 (98.1) 98.9 (96.6)
b 93.9 (94.3) 100.0 (100.0)
Redundancy 6.9 (5.4) 4.8 (4.2) 7.5 (7.1)
b 6.9 (5.4) 6.5 (6.2)
Refinement Resolution (A ˚) 28.5–1.95 23.6–1.90 19.8–1.80 36.0–1.32 30.00–1.92
No. reflections 17057 18690 21674 51201 15984
Rwork / Rfree 0.219 / 0.263 0.213 / 0.251 0.175 / 0.209 0.242 / 0.259 20.9 / 24.1
No. atoms 1574 1691 1770 1752 1542
Protein 1480 1559 1581 1587 1457
Ligand/ion 28 29 23 23 50
Water 66 103 166 142 35
B-factors (A ˚2) 22.91 26.14 18.24 12.64 33.2
Protein 22.90 26.08 17.65 12.18 33.2
Ligand/ion 22.99 24.06 27.88 16.13 33.1
Water 23.13 27.56 22.55 17.24 31.7
RMS deviations Bond lengths(A ˚) 0.016 0.016 0.017 0.018 0.017
Bond angles (8) 1.5 1.3 1.5 1.5 1.4
Ramachandran
plot % residues
Favored 93.1 93.3 94.0 94.0 91.7
Additional allowed 6.9 6.7 5.4 6.0 8.3
Generously allowed None None 0.6 None None
Disallowed None None None None None
a Under these conditions, only NR was found in the structure. In 35% PEG 2000 mono-methylether, 0.1 M Tris, pH 8.0, Nrk1 crystallized in a tetragonal space group and both NR and
AppNHp were enzyme-bound.
b Bijvoet pairs were scaled separately.
RMS, root mean square;
doi:10.1371/journal.pbio.0050263.t002
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þHowever, in the ATP-speciﬁc Nrk2 sequence, Glu174 is
replaced with Arg. Indeed, in a large study of amino acid
propensity in adenine and guanine-binding sites, Arg was
found to be localized at adenine sites and to be largely
excluded from guanine sites [31].
To determine the nature of nucleoside phosphorylation by
Nrk1, we co-crystallized the Nrk1 enzyme with NR,
NR Mg
2þ AppNHp, NMN, and tiazofurin, and performed
molecular replacement and reﬁnement to obtain high-
resolution models. Despite the typical hinge motions identi-
ﬁed in Rossmann fold-containing metabolite kinases upon
substrate-binding [32], Nrk1 was neither opened nor closed
by any ligands examined. Pairwise comparisons of the a
carbon coordinates indicated that all structures are within a
root mean square difference of less than 0.4 A ˚ . As shown in
Figure 2B, which is derived from a 1.32-A ˚ crystal structure,
NR is bound with the 29 and 39 hydroxyl groups recognized by
bidentate interactions from Asp56 and Arg129 and with the
carboxylate of Asp36 accepting an apparent hydrogen bond
from the NR 59 hydroxyl. Such a hydrogen bond could serve
to activate the 59 oxygen toward bond formation with the c
phosphorous atom of a bound ATP substrate.
As shown in Figure 2C, in the 1.92-A ˚ reﬁned crystal
structure of Nrk1 bound to the hydrolysis-resistant ATP
analog AppNHp with Mg
2þ and NR, the c phosphate—
recognized by side chains of Thr12, Lys16, Tyr134, and
Arg132—is positioned for potential in-line transfer to the 5’
oxygen of NR. In this structure, the carboxylate of Asp36 is a
direct Mg
2þligand. In the NMN product complex (Figure 2D),
all four side chains ‘‘formerly’’ associated with the c
phosphate of AppNHp are associated with the a phosphate
of NMN, suggesting that these residues may be optimally
aligned to stabilize a putative pentacoordinate phosphorane
transition state that is resolved either by collapse to ATP þ
NR or by the formation of ADP þ NMN products.
Essential Carboxylates at the Nrk1 and Nrk2 Active Sites
In the NR (Figure 2B) and NMN (Figure 2D) substrate and
product complexes, Asp36 is oriented toward the 59’ oxygen,
suggesting a role in activating the acceptor oxygen and
promoting bond formation. In the absence of NR or NMN
and in the presence of the ADP product (Figure 2A), Asp36
stabilizes a Mg
2þ-associated water molecule. Curiously, Asp36
has yet a third unique conformation in the inactive bi-
substrate analog complex (Figure 2C). In addition, Glu98
appears to have a key role in organizing a stable water ligand
of Mg
2þ. To test the hypothesis that Asp36 and Glu98
(residues 35 and 100 in Nrk2) might be essential for function,
we constructed human nrk1-D36A, nrk1-E98A, nrk2-D35A, and
nrk2-E100A alleles for evaluation in yeast. These mutants,
alongside wild-type NRK1 and NRK2 controls, were intro-
duced into yeast strain BY278 in which NRK alleles were
expressed from the GAL1 promoter on a LEU2 plasmid, the
endogenous NRK1 gene was deleted, and a QNS1 gene was
provided on a URA3 plasmid. In this system, a functional
NRK gene allows a yeast cell grown in the presence of 10 lM
NR to lose the QNS1 gene with associated URA3 marker, as
scored by resistance to 5-ﬂuoro-orotic acid [4]. As shown in
Figure 3, the conserved Asp and Glu residues are required for
function of Nrk enzymes in vivo. To exclude the possibility
that the conserved Glu residues are required for folding and
are potentially dispensable after protein biosynthesis, we
expressed and puriﬁed nrk1-E98A and nrk2-E100A mutant
proteins in E. coli. As shown in Figure S1, the conserved Glu is
not required for soluble expression, accumulation, puriﬁca-
tion, or concentration. Although nrk1-E98A and nrk2-E100A
proteins behaved precisely as did wild-type enzymes in
puriﬁcation, their activity in ATP-dependent phosphoryla-
tion of NR was below the level of detection of our assay. Thus,
Asp36 (Asp35 in Nrk2) and Glu98 (Glu100 in Nrk2) are
essential residues for function in vivo. The demonstrated
post-biosynthetic role for the conserved Glu and the
conserved active-site positions of Glu and Asp strongly argue
for roles in catalysis.
Base Recognition in the Nrk1 Nucleoside-Binding Site
Excludes Uridine but Supports NaR Phosphorylation
Data in Table 1 show that Nrk1 has strong speciﬁcity for
nucleosides containing a carboxamide group two bond
lengths away from N1, such as NR and tiazofurin, and
features that may discriminate against the 2- and/or 4-
substitutions found in cytidine and uridine. Indeed, in crystal
structures of Nrk1 bound to NR and NMN, it is clear that the
4-amino group of cytidine or the 4-oxy group of uridine
could not be accommodated without rearrangement, because
these constituents would clash with the carbonyl oxygen of
Gln135, which is in a cis peptide linkage with Pro136. This
unique backbone conformation is unlikely to be conserved by
the uridine-accepting Nrk2 enzyme, which has a Thr-Val
sequence in this position, likely to be in the typical trans
conformation. The van der Waals clash between a modeled 4-
oxy group of uridine and the Gln135 carbonyl oxygen is
shown in Figure 4.
The carboxamide-containing preferred nucleoside sub-
strates of Nrk1 are tiazofurin and NR. As shown in Figure
5A, the two nucleosides are bound almost superimposably by
Nrk1. The pyridine and thiazole moieties of NR and
tiazofurin, respectively, are stacked between the phenol rings
of Tyr55 and Tyr134. An additional aromatic interaction with
Phe39 allows the polar carbonyl oxygen and amino groups of
NR and tiazofurin to be exposed to solvent (Figure 5B).
Because carbonyl oxygen and amino groups are isosteric at
Figure 1. Nrk1 Is a Rossmann Fold Metabolite Kinase
(A) Ribbon diagram of Nrk1 bound to ADP with rainbow coloring from
the N terminus (violet) to the C terminus (red). Helices A through E,
strands 1 through 5, and the lid domain are indicated. (B) Structural
superposition of Nrk1 (blue) with human Uck2 (red).
doi:10.1371/journal.pbio.0050263.g001
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þ1.9-A ˚ resolution, we looked for an electrostatic interaction
that might uniquely orient the carboxamide function of NR
and tiazofurin, and found no interacting residue within
hydrogen-bonding distance. We therefore considered the
possibility that Nrk enzymes might phosphorylate the
isosteric but nonisoelectronic NR analog, NaR. Consequently,
NaR was synthesized and examined as an in vitro substrate of
Nrk1 and Nrk2. As shown in Table 1, NaR is phosphorylated
by Nrk1 and Nrk2 with highly similar kinetics with respect to
those for NR phosphorylation. In assays of each human
enzyme, NaR is favored over NR by slight KM advantages
offset by slight kcat disadvantages. In kcat/KM terms, Nrk1 has
60% of the activity and Nrk2 has 138% of the activity with
NaR versus NR. Thus, human Nrk1 and human Nrk2 are dual-
speciﬁcity, NR and NaR kinases.
NaR Is a Novel NAD
þ Precursor Utilized via the Nrk and
Preiss-Hander Pathways
The steric complementarity of Nrk1 with NR and the lack
of electrostatic exclusion of NaR by human Nrk1 and Nrk2
suggested that NaR might be a synthetic NAD
þ precursor
vitamin. Should NaR be utilized by yeast cells, it would be
conceivable that NaR is a previously unrecognized metabo-
lite, such that the utility of NaR salvage might have played a
role in the evolution of Nrk speciﬁcity. Additionally, our
discovery of Nrk1-dependent [4] and Nrk1-independent [15]
NR utilization suggested that, should NaR support the
Figure 2. Nucleoside and Nucleotide Recognition by Nrk1
Stereo diagrams of Nrk1 are provided in a consistent orientation using the main chain backbone colors from Figure 1A. (A) ADP Mg
2 product complex
with the corresponding difference electron density map, contoured at 3.0 A ˚. (B) NR substrate complex. (C) Bisubstrate analog complex of AppNHp Mg
2
plus NR. (D) NMN product complex.
doi:10.1371/journal.pbio.0050263.g002
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þvitamin requirement of de novo pathway–deﬁcient yeast cells,
there could be two different metabolic pathways for NaR
utilization. As shown in Figure 6A and 6B, the bna1 mutant in
de novo biosynthetic enzyme 3-hydroxyanthranilic acid
dioxygenase is a Na auxotroph [33] that can also be supported
by 10 lM NR, thus providing an assay for vitamin activity of
NaR. As reported earlier [4], NR can bypass the requirement
of glutamine-dependent NAD
þ synthetase, Qns1 [21]. Also
shown in Figure 6B, NR keeps a bna1 mutant alive in two
different ways because cells have two NR salvage pathways
[15]. The ﬁrst NR salvage pathway goes through Nrk1, which
allows NR-dependent viability in a bna1 mutant deleted for
Npt1, which is the Na phosphoribosyltransferase. The second
NR salvage pathway depends on the NR-splitting activities of
Urh1 and Pnp1, followed by nicotinamidase and Npt1
activities. This pathway allows a bna1 nrk1 double mutant to
retain viability. The two NR salvage pathways are schematized
in the lower right section of Figure 7.
As shown in Figure 6C, 10 lM NaR can also be used by bna1
mutants, establishing that NaR is a transportable NAD
þ
precursor vitamin. Genetic control over NAD
þbiosynthesis in
the yeast system allowed us to establish that NaR is not simply
used as Na, not contaminated by or converted to NR, and is
used via a unique set of enzymes including Nrk1, Urh1 and
Pnp1, and Qns1. If NaR were merely a source of Na, the bna1
npt1 mutant would fail to grow on NaR. However, Figure 6C
clearly shows that NaR supports the growth of bna1 npt1
mutant yeast cells. Moreover, if NaR were either contami-
nated by NR or converted to NR by any cellular process, then
NaR would support the growth of the qns1 mutant. As shown
in Figure 6C, NaR fails to support the growth of the qns1
mutant. Whereas NaR shares with NR the ability to be utilized
by bna1 npt1 and bna1 nrk1 mutants, the Qns1 requirement for
NaR indicates that NaR metabolites must ﬂow through
nicotinic acid mononucleotide (NaMN) and nicotinic acid
adenine dinucleotide (NaAD) as schematized in Figure 7.
Vitamin activity of NaR in bna1 npt1 and bna1 nrk1 mutant
strains can be explained by two pathways for NaR utilization.
NaR is phosphorylated by Nrk1 with highly similar kinetics to
those of NR (Table 1). Thus, phosphorylation of NaR by Nrk1
produces NaMN in a pathway that is independent of Npt1. By
analogy with the recently described Nrk1-independent NR
utilization pathway, we hypothesized that NaR is a substrate
of the nucleoside hydrolase and nucleoside phosphorylase
activities of Urh1 and Pnp1, which are responsible for
virtually all Nrk1-independent NR salvage [15]. However,
whereas yeast Nrk1-independent NR salvage requires nicoti-
namidase, the corresponding pathway for NaR would simply
produce Na from NaR, which would be salvaged by the Preiss-
Handler pathway [34], consisting of Na phosphoribosyltrans-
ferase Npt1 [7], Nma1,2, and Qns1.
To test the hypothesis that NaR utilization depends on
Nrk1, Urh1, and Pnp1, i.e., the same enzymes that initiate NR
salvage [15], we grew wild-type, npt1 mutant, nrk1 mutant,
urh1 pnp1 mutant, and nrk1 urh1 pnp1 mutant cells in vitamin-
free media and in vitamin-free media supplemented with 10
Figure 4. NR/Uridine Discrimination by Nrk1
In stereo, the 2- and 4-oxy functions (black) of a hypothetical uridine substrate are shown superimposed onto NR coordinates in the Nrk1 NR co-crystal
structure. At a distance of 2.55 A ˚, the 4 oxygen would be in van der Waals conflict with the carbonyl oxygen of Gln135, which is in a cis peptide linkage
with Pro136.
doi:10.1371/journal.pbio.0050263.g004
Figure 3. Active Site Requirement of Nrk1 and Nrk2
The conserved carboxylates of human Nrk1, Asp36 and Glu98, and the
corresponding carboxylates of Nrk2 are required for biological activity in
yeast.
doi:10.1371/journal.pbio.0050263.g003
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þlM NaR. As shown in Figure 6D, NaR elevates NAD
þ levels in
all strains except the nrk1 urh1 pnp1 mutant. In the wild-type
strain, NaR elevated intracellular NAD
þfrom 0.70 6 0.04 mM
to 1.18 6 0.10 mM, an increase of 480 lM. This can be
compared with the 1.21 mM increase in intracellular NAD
þ
that is produced by growing wild-type cells in 10 lM NR [15].
Elimination of Nrk1 or both Urh1 and Pnp1 produced an
identical 40% decline in the ability of NaR to elevate NAD
þ.
In the nrk1 mutant, NAD
þ was elevated from 0.70 6 0.03 mM
to 0.99 6 0.05 mM, whereas NAD
þ was elevated from 0.70 6
0.01 mM to 0.99 6 0.02 mM in the urh1 pnp1 double mutant.
Two strains, namely the npt1 mutant (0.59 6 0.001 mM),
which is deﬁcient in the NAD
þ salvage necessitated by Sirtuin
activity [7], and the nrk1 urh1 pnp1 mutant (0.60 6 0.02 mM),
which is deﬁcient in NR utilization and salvage [15], have
baseline NAD
þ concentrations in vitamin-free media that are
110 lM and 100 lM lower than those of the other strains,
respectively. However, whereas the npt1 mutant was increased
to 0.73 6 0.03 mM with addition of NaR, the triple mutant in
NR utilization was unable to obtain an increase in NAD
þ
concentration in response to NaR (0.59 6 0.02 mM).
Thus, NaR is a synthetic vitamin precursor of NAD
þ that is
phosphorylated by Nrk enzymes in vitro (Table 1) and utilized
in vivo (Figure 6). In vivo utilization of NaR is not limited to
the Nrk pathway producing NaMN, because NaR can fulﬁll
the vitamin requirement of a bna1 nrk1 mutant, and NaR can
elevate NAD
þ in cells without Nrk1. Just as NR salvage goes
through Nrk and Urh1/Pnp1 pathways [15], the nucleoside-
splitting activities of Urh1 and Pnp1 and Nrk1 must be
eliminated to block NaR utilization. Yeast NAD
þ biosynthetic
pathways updated to include NaR utilization are schematized
in Figure 7.
Discussion
The experiments performed herein establish that Asp36
and Glu98 have essential roles in Nrk function. Structures of
Nrk1 bound to adenosine nucleotides and pyridine and
thiazol nucleoside substrates provided information of the
basis for ATP/GTP nondiscrimination and pyrimidine ex-
clusion by Nrk1. Structural analysis of Nrk2 is expected to
shed light on how Nrk2 excludes GTP and phosphorylates
uridine.
It has been established that no yeast enzyme can substitute
for Nrk1 in conversion of NR to NMN in vivo [4]. Moreover,
the postulated role for Nrk enzymes in phosphorylating NR-
mimetic prodrugs has created expectations for strong
speciﬁcity in carboxamide recognition. Structures of Nrk1
with NR and tiazofurin, however, indicated that the nucleo-
sides are recognized by polar interactions with the 29,3 9, and
59 hydroxyl groups and aromatic interactions with the base.
Whereas there are steric clashes that would appear to
destabilize the 4-substitutions found in cytosine and uracil
(Figure 4), there is steric complementarity for the 3
carboxamide moiety in NR (Figure 5B). Recognizing the
absence of an enzyme feature that would speciﬁcally orient
the carboxamide group, we synthesized NaR and discovered
that both Nrk1 and Nrk2 are dual-speciﬁcity NR and NaR
kinases (Table 1). To determine whether this speciﬁcity is
merely a biochemical curiosity or might indicate another
cellular function, we determined whether yeast cells deﬁcient
in de novo NAD
þbiosynthesis can use NaR in vivo. According
to genetic data presented in Figure 6 and schematized in
Figure 7, NaR is used via Na salvage and via Nrk1-dependent
production of NaMN. The Nrk-dependent and Nrk-inde-
pendent salvage of NaR is precedented by the processes by
which NR is utilized in yeast cells. NR is utilized in an Nrk-
dependent process that does not depend on the glutamine-
dependent NAD
þ synthetase [4]. However, NR is also utilized
in a process that depends on NR splitting by Urh1, Pnp1 and
Meu1, the Pnc1 nicotinamidase, and the Preiss-Handler
pathway [15]. The unique feature of NaR as an in vivo
substrate of the Nrk pathway is that NaR requires Nrk and
NAD
þ synthetase.
The importance of the dual speciﬁcity of Nrk enzymes at
phosphorylating NR and NaR is three-fold. First, there are
active programs to design prodrugs of NAD
þ-antagonistic
compounds such as TAD and benzamidine adenine dinucleo-
tide. It has been assumed that such prodrugs must not stray
far from NR to allow phosphorylation, adenylylation, and
Figure 5. NR and Tiazofurin Recognition by Nrk1
(A) Coordinates of tiazofurin, in yellow, are superimposed with those of NR in isomorphous crystal structures. The sulfur atom of tiazofurin was localized
by the 3 A ˚ anomalous difference Fourier map, contoured in purple at 2.7 A ˚. (B) A surface representation of the Nam binding-site of NR reveals no
specific recognition of the carboxamide group, which is exposed to solvent.
doi:10.1371/journal.pbio.0050263.g005
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þinhibition of the target dehydrogenases [35]. However, the
discovery that Nrk1 and, apparently, Nrk2 exhibit steric but
not electrostatic recognition of the carboxamide group will
allow a wider range of prodrugs to be synthesized and
evaluated.
Second, the abilities of yeast to use NaR and of human Nrk
enzymes to phosphorylate NaR in vitro suggest that NaR
might be useful as a vitamin precursor to NAD
þ. However,
because Nrk-independent salvage requires expression of all
three Preiss-Handler enzymes, Nrk-independent utilization
of NaR would amount to supplementing with a very
expensive form of Na. This is impractical because Na is
already readily available in the diet and may be tissue-limited
by the expression of Na phosphoribosyltransferase. Because
maturation of NaR to NAD
þ through the Nrk pathway
requires the activity of NAD
þ synthetase, NaR might be more
tissue-restricted than NR or constitute a slower-release
niacin-equivalent than NR. Thus, it is conceivable that NaR
could be a useful supplement, particularly if it largely evades
Nrk-independent phosphorolysis to Na or, as suggested for
NR [15], if NaR phosphorolysis can be inhibited, presumably
with a Pnp inhibitor.
Finally, the biotransformation of NaR by the two NR
salvage systems in yeast prompts us to ask whether NaR might
be an endogenous metabolite, such that the utility of NaR
phosphorylation could have played a role in maintaining dual
NR/NaR substrate speciﬁcity. NR was initially characterized as
a compound produced in the laboratory and found in milk
that can provide for qns1-independent yeast cell growth when
added exogenously [4]. Exogenously applied NR protects
against transection-induced degeneration of murine dorsal
root ganglion neurons [16]. In the yeast system, exogenously
applied NR increases NAD
þ levels, Sir2 function, and
replicative life span [15]. Additionally, the yeast study
provided evidence for an endogenous NAD
þ catabolic
process that creates a requirement for NR salvage enzymes
to maintain NAD
þ levels [15]. By deleting the NRK1, URH1,
and PNP1 genes, which account for virtually all NR utilization
through both the Nrk-dependent and the Nrk-independent
pathways, we showed that there is a signiﬁcant (0.8 mM)
deﬁciency in NAD
þ levels in cells grown in standard media,
which does not contain any NR [15]. These data strongly
argue for an endogenous process that produces NR and/or
NaR at the expense of NAD
þ. Indeed, because npt1 and nrk1
urh1 pnp1 mutants have the same deﬁciency in baseline NAD
þ
levels in vitamin-free media (Figure 6D), we suggest that the
rate of NAD
þ catabolism to NR and/or NaR is comparable to
the rate of Sirtuin-dependent consumption of NAD
þ to Nam.
Figure 6. NaR Utilization In Vivo
In (A), the vitamin requirement of de novo mutant bna1 and glutamine-
dependent NAD
þ synthetase mutant qns1 is illustrated. The fact that
bna1, bna1 nrk1, bna1 npt1, and qns1 strains are satisfied by addition of
NR is shown in (B). In (C), the vitamin activity of NaR is demonstrated for
the de novo mutant bna1, even when either the Nrk pathway or the
Preiss-Handler pathway is mutationally inactivated by nrk1 or npt1
mutation, respectively. Establishing the uniqueness of NaR as a vitamin,
NaR fails to support the growth of qns1. In (D), the intracellular NAD
þ
concentration is calculated for wild-type, npt1, nrk1, urh1 pnp1, and nrk1
urh1 pnp1 mutants in vitamin-free (gray bars) and in vitamin-free media
supplemented with 10 lM NaR (black bars). The unique lack of utilization
by the nrk1 urh1 pnp1 strain shows that NaR makes use of Nrk1, Urh1,
and Pnp1 for conversion to NAD
þ.
doi:10.1371/journal.pbio.0050263.g006
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þMaterials and Methods
Enzyme puriﬁcation and characterization. His-tagged human Nrk1
and Nrk2 proteins were expressed and puriﬁed from E. coli strain
BL21(DE3) as described [4]. Kinetic analyses were performed in 20
mM HEPES, pH 7.5, 100 mM NaCl, 5 mM MgCl2 with 1 mM ATP or
GTP as phosphodonor and with varying concentrations of nucleoside
substrates. Reactions were initiated by Nrk1 or Nrk2 enzyme
sufﬁcient to convert 1% to 10% of the input nucleoside to nucleoside
monophosphate in 30 min incubations at 37 8C. Products were
quantiﬁed by anion exchange high-performance liquid chromatog-
raphy (HPLC) as described [4] and kinetic parameters were
determined from Lineweaver-Burke plots.
Crystallization, structure determination, and reﬁnement. Nrk1 (30
mg/ml) was crystallized by 1:1 sitting drop vapor diffusion (18 8C)
against the reservoir solutions listed in Table 2. Crystals were cryo-
protected in 1:1 paratone and mineral oil. Diffraction data (Table 2)
were reduced to intensities with the HKL2000 suite [36], and the ﬁrst
Nrk1 structure was solved de novo as described in the text. ARP/
wARP [37] was used for model building, and PHASER [38] was used
for molecular replacement of subsequent Nrk1 structures. Geometric
restrains for NR, NMN, and tiazofurin were generated on the
PRODRG server [39]. Restrained reﬁnement using REFMAC [40],
geometric validation using MOLPROBITY [41], and manual rebuild-
ing using COOT [42] were performed iteratively until convergence
(Table 2). Coordinate alignments were performed by secondary
structure matching [43] within COOT. Molecular graphics were
produced with PyMOL [39]. Structure factors and coordinates have
been deposited in the Protein Data Bank.
Synthesis of NaR. Trimethylsilyl triﬂuoromethanesulfonate (1.039
g, 4.4 mmol; Sigma-Aldrich; http://www.sigmaaldrich.com) was slowly
added to ethyl nicotinate (0.9 ml, 6.6 mmol; Sigma-Aldrich) and
1,2,3,5-tetra-O-acetyl-b-D-ribofuranose (1.4 g, 4.4 mmol; Sigma-
Aldrich) in 50 ml anhydrous methylene chloride at room temper-
ature, stirred under argon. The mixture was heated to reﬂux for 8 h.
TLC (CH2Cl2: MeOH: TEA¼5: 0.3: 0.05) stained with 10% H2SO4 in
MeOH showed the disappearance of the ribofuranose and appear-
ance of the presumed product, 29,3 9,5 9-triacetyl ethyl NaR in a single
spot at lower mobility relative to the front. After evaporation of
methylene chloride, product (25 mg, 0.05 mmol) was added into 0.9
ml of 312 mM NaOEt in EtOH on ice to form O-ethyl b-NaR. After
mixing well, the reaction was stored at 20 8C overnight. The reaction
was quenched with addition of acetic acid to neutralize the pH. After
organic solvent was removed in vacuum, the residue was dissolved in
water and extracted with cyclohexane to remove organic impurities.
The aqueous phase was then concentrated 10-fold, made to 150 mM
in phosphate buffer, and provided with 10 ll of pig liver esterase (13
units; Sigma-Aldrich) to release NaR in a 25 8C overnight incubation.
NaR was puriﬁed by C-18 HPLC. NaR was assayed by MALDI MS, in
positive ion detection mode, and was observed as the protonated
molecular ion (predicted mass-to-charge ratio m/z¼ 256.08, observed
m/z¼ 256.1). Other assignable fragmented ions detected included
protonated Na. The entire m/z spectrum (% peak height) was 256.1
(1.81%), 228.0 (48.5%), 207.1 (25.4%), 146.1 (10.3%), and 124.0
(13.9%). We used a molar extinction coefﬁcient of 6411 cm
 1 (260
nm) for NaR and 4305 cm
 1 (259 nm) for NR.
S. cerevisiae strains, plasmids, and media. Yeast strain BY278, which
contains qns1 deletion covered by plasmid pB175 (QNS1 and URA3)
and which contains nrk1 deletion, has been described [4]. pB450 and
pB459, which are LEU2 plasmids for expression of human NRK1 and
NRK2 cDNAs under GAL1 promoter control [4], were used as
templates for site-directed mutagenesis to produce nrk1-D36A
(pHC12), nrk1-E98A (pHC10), nrk2-D35A (pHC13), and nrk2-E100A
(pHC11). BY278 was transformed with each plasmid and the empty
p425GAL1 control. After passage on galactose media, transformants
were streaked on synthetic complete, galactose media with 5-
ﬂuoroorotic acid and 10 lM NR [4] to score the function of NRK
alleles. Isogenic strains for the NaR utilization study were BY165-1d
(qns1) [4], KB046 (bna1 in the deletion consortium background [44]),
KB056 (nrk1 deleted from KB046), and JS949 (bna1 npt1, a gift of
Jeffrey S. Smith, University of Virginia, United States). The four
strains were grown in synthetic media with 3 lM Na plus 10 lM NR,
washed in saline, and then cultured to exhaustion in vitamin-free
media [15]. To assay utilization of NR or NaR, strains grown to
exhaustion in vitamin-free media were streaked on vitamin-free
synthetic media supplemented with 10 lM NR or NaR and photo-
graphed after 3 d at 28 8C. NAD
þ measurements were performed as
described [15] with isogenic yeast strains grown in vitamin-free media
and vitamin-free media supplemented with 10 lM NaR to an optical
density (OD)600 nm of 1. Strains were wild-type BY4742, KB009 (nrk1
in the deletion consortium background [44]), KB008 (npt1 in the
deletion consortium background [44]), PAB047 (urh1 pnp1 [15]) and
PAB038 (urh1 pnp1 nrk1 [15]).
Supporting Information
Figure S1. Expression and Activity Analysis of Nrk Active-Site
Glutamate Mutants
His-tagged human wild-type Nrk1 and Nrk2 and glutamate mutants
were expressed and puriﬁed from E. coli by immobilized cobalt
afﬁnity chromatography. The expression and puriﬁcation of wild-
type Nrk2 and Nrk2-E100A were analyzed by SDS-PAGE. Both Nrk2
and Nrk2-E100A exhibited high-level overexpression in the total cell
lysate and virtually identical behavior upon chromatography. Relative
speciﬁc activities were calculated for Nrk1, Nrk1-E98A, Nrk2, and
Nrk2-E100A. Reactions contained 1 mM ATP as phosphodonor and 1
Figure 7. NAD
þ Metabolism in Yeast: Two New Pathways to NaMN
Previously reported NAD
þ metabolic pathways are shown in black[15]. In blue and green, respectively, are Nrk1-dependent and Nrk1-independent
routes from NaR to NaMN.
doi:10.1371/journal.pbio.0050263.g007
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þmM NR as nucleoside acceptor. Reactions were incubated for 30 min
at 37 8C. NMN was quantiﬁed by anion exchange HPLC.
Found at doi:10.1371/journal.pbio.0050263.sg001 (74 KB DOC).
Accession Numbers
The Swiss-Prot (http://www.ebi.ac.uk/swissprot) accession numbers for
proteins in this paper are: human MTAP (Q13126); human Nrk1
(Q9NWW6); human Nrk2 (Q9NPI5); human NP (P00491); human Uck2
(Q9BZX2); S. cerevisiae Bna1 (P47096); S. cerevisiae Meu1 (Q07938); S.
cerevisiae Npt1 (P39683); S. cerevisiae Nrk1 (P53915); S. cerevisiae Pnc1
(P53184); S. cerevisiae Pnp1 (Q05788); S. cerevisiae Qns1 (P38795); S.
cerevisiae Urh1 (Q04179); E. coli gntK (P46859); E. coli panK (P0A615);
and B. stearothermophilus adk (P27142). The Protein Data Bank (PDB)
(http://www.rcsb.org/pdb) accession numbers for human Nrk1 are
2QSY, 2QT1, 2QT0, 2QSZ, and 2P0E; for human Uck2 is 1UJ2.
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